LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled "Monoclonal Antibodies with Enhanced ADCC Function" on April 26, 2011, by the U.S. Patent and Trademark Office (USPTO). The new patent covers monoclonal antibodies having an enhanced antibody-dependent cellular cytotoxicity (ADCC) due to an improved glycosylation profile for fucose.

Commenting on this important development, LFB's CEO Christian Béchon stated, "We are very pleased to expand our patent coverage in this promising area of monoclonal antibody technology. This U.S. patent is key to furthering our development of a portfolio of monoclonal antibodies".

Source: LFB